http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018508540-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 2016-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2018508540-A |
| titleOfInvention | Frontal lobe dysfunction treatment |
| abstract | According to the present invention, for example, frontal lobe dysfunction (for example, cognitive impairment (for example, cognitive impairment in Parkinson's disease, cognitive impairment due to chronic stress) containing the compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient , Lewy body dementia, progressive supranuclear palsy, frontotemporal dementia, etc.), Lewy body disease (eg cognitive impairment in Parkinson's disease, diffuse Lewy body disease, Lewy body disease type) A therapeutic and / or prophylactic agent for dementia, movement disorder in Lewy body disease, etc.). [Selection figure] None |
| priorityDate | 2015-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 60.